Core Insights - Iovance Biotherapeutics is under investigation for potential violations of federal securities laws and unlawful business practices [1] - The company reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million, down from $73.7 million in the previous quarter [3] - Iovance has revised its full fiscal year 2025 revenue guidance from a range of $450 million-$475 million to $250 million-$300 million, representing a reduction of over 40% at the midpoint [3] - Following the announcement, Iovance's share price dropped by $1.42, or approximately 44%, closing at $1.75 on May 9, 2025 [3] Company Performance - The first quarter 2025 product revenue of $49.3 million indicates a significant decrease compared to the previous quarter's revenue of $73.7 million [3] - The revision of the full-year 2025 revenue guidance reflects challenges in the launch dynamics of the T cell immunotherapy, Amtagvi (lifileucel), which was launched in the U.S. in the first half of 2024 [3] Market Reaction - The announcement of the revenue decline and guidance revision led to a sharp decline in Iovance's stock price, falling from $3.17 to $1.75 within a day [3]

Core Viewpoint - A class action lawsuit has been filed against Digimarc Corporation for failing to disclose significant information regarding its commercial contracts, leading to a substantial drop in its stock price and revenue [1][4]. Financial Performance - Digimarc reported a 10% decrease in quarterly subscription revenue, falling to $5.0 million from $5.6 million year-over-year [3]. - The annual recurring revenue (ARR) decreased to $20.0 million from $22.23 million in the previous year, primarily due to a $5.8 million decline linked to the expiration of a commercial contract in June 2024 [3]. - Following the announcement of these financial results, Digimarc's share price plummeted by $11.65, approximately 43%, from $27.04 to $15.39 per share [3]. Legal Allegations - The lawsuit alleges that Digimarc failed to disclose that a major commercial partner would not renew a significant contract under the same terms, which would lead to renegotiation and negatively impact subscription and annual recurring revenue [4].

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Compass Diversified Holdings (“Compass” or the “Company”) (NYSE:CODI). The investigation concerns whether Compass and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 7, 2025, after the markets closed, Compass filed a Form 8-K which stated that the Audit Committee of Board ...

Core Viewpoint - Perpetua Resources Corp. faces a federal securities class action due to undisclosed material information regarding increased capital expenditures for its Stibnite Gold Project, leading to a significant drop in share price [1][3][4]. Group 1: Class Action Details - The law firm Kirby McInerney LLP is notifying investors of a deadline on May 20, 2025, to seek the role of lead plaintiff in the class action [1]. - The class action pertains to investors who acquired Perpetua securities between April 17, 2024, and February 13, 2025 [1]. Group 2: Financial Impact - On February 13, 2025, Perpetua announced an updated cash flow model revealing additional capital expenses of $952 million, which is over a 75% increase from initial estimates [3]. - Following this announcement, Perpetua's share price fell by $2.68, approximately 22%, from $11.97 to $9.29 per share [3]. Group 3: Allegations - The complaint alleges that Perpetua failed to disclose material information regarding expected initial capital expenditures for the Stibnite Gold Project during the class period [4].

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against SelectQuote, Inc. (“SelectQuote” or the “Company”) (NYSE:SLQT). The investigation concerns whether SelectQuote and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a False Claims Act complaint against SelectQuote, alleging that ...

Core Viewpoint - Kirby McInerney LLP is investigating potential claims against GoHealth, Inc. regarding possible violations of federal securities laws and unlawful business practices [1] Group 1: Legal Investigation - The investigation focuses on whether GoHealth and/or its officers have engaged in unlawful business practices [1] - The U.S. Department of Justice filed a complaint against GoHealth, alleging that the company received illegal kickbacks from insurers for enrollments in Medicare Advantage plans [3] Group 2: Financial Impact - Following the DOJ complaint, GoHealth's share price dropped by $1.09, from $10.53 on April 30, 2025, to $9.44 on May 1, 2025 [3]

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Humana Inc. (“Humana” or the “Company”) (NYSE:HUM). The investigation concerns whether Humana and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, the U.S. Department of Justice filed a complaint against insurance broker organizations, including Humana, alleging t ...

Core Viewpoint - A class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. for misleading investors regarding the approval prospects of its Biologics License Application for lomab-B, leading to significant stock price decline [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the U.S. District Court for the Southern District of New York on behalf of investors who acquired Actinium securities from October 31, 2022, to August 2, 2024 [1]. - Investors have until May 27, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Regulatory Update - On August 5, 2024, Actinium announced that the FDA determined the data from its Sierra trial did not support a BLA filing for lomab-B, necessitating an additional clinical study [3]. - Following this announcement, Actinium's share price fell by $3.69, or approximately 59%, from $6.17 on August 2, 2024, to $2.48 on August 5, 2025 [3]. Group 3: Allegations - The complaint alleges that during the Class Period, Actinium misled the market into believing that the data submitted for its BLA would meet FDA guidelines for acceptance and approval [4].

NEW YORK , May 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ:ARVN). The investigation concerns whether Arvinas and/or certain of its officers have violated the federal securities laws. [LEARN MORE ABOUT THE INVESTIGATION] On May 1, 2025, Arvinas and its partner Pfizer announced that they would discontinue development of vepdegestrant, an oral SERD for HR-positive breast cancer. The move eliminated ...

Core Viewpoint - A federal securities class action has been filed against Ultra Clean Holdings, Inc. due to undisclosed material information regarding demand from Chinese OEMs during the fiscal year 2024, leading to significant stock price decline [1][3][4]. Company Summary - Ultra Clean Holdings, Inc. experienced a notable decline in stock price, dropping approximately 28% from $36.06 to $25.90 following the announcement of "demand softness" in China on February 24, 2025 [3]. - The company faced decreased demand attributed to extended qualification timelines and inventory absorption in the Chinese market [3]. Legal Action Summary - The law firm Kirby McInerney LLP is notifying investors of a deadline on May 23, 2025, to seek the role of lead plaintiff in the class action lawsuit [1]. - The complaint alleges that Ultra Clean failed to disclose critical information regarding elevated demand from Chinese OEMs and the domestic market throughout fiscal year 2024 [4].